SBOT - Stellar Biotechnologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1600
0.0000 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1600
Open1.1700
Bid0.96 x 1800
Ask1.23 x 800
Day's Range1.1288 - 1.2042
52 Week Range0.7500 - 7.6300
Volume40,766
Avg. Volume235,226
Market Cap6.184M
Beta (3Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateFeb 6, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Stellar Biotechnologies Reports First Quarter Financial Results
    PR Newswire17 days ago

    Stellar Biotechnologies Reports First Quarter Financial Results

    LOS ANGELES , Feb. 5, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, ...

  • How Much Did Stellar Biotechnologies, Inc.’s (NASDAQ:SBOT) CEO Pocket Last Year?
    Simply Wall St.last month

    How Much Did Stellar Biotechnologies, Inc.’s (NASDAQ:SBOT) CEO Pocket Last Year?

    Frank Oakes became the CEO of Stellar Biotechnologies, Inc. (NASDAQ:SBOT) in 2010. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...

  • Zacks Small Cap Research3 months ago

    SBOT: Q4 Update: Neovacs IFN-K Development Accelerating Following Positive Ph2 Results

    Stellar (SBOT) reported financial results for their fiscal fourth quarter ending September 30th. Importantly, indications are that clinical trial and overall product development progress continues of those therapeutic candidates that SBOT supplies with their KLH. This includes Neovacs’ IFNa-Kinoid (IFN-K) development program.

  • Is Stellar Biotechnologies Inc’s (NASDAQ:SBOT) Balance Sheet A Threat To Its Future?
    Simply Wall St.3 months ago

    Is Stellar Biotechnologies Inc’s (NASDAQ:SBOT) Balance Sheet A Threat To Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Stellar Biotechnologies Inc (NASDAQ:SBOT), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results
    PR Newswire3 months ago

    Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results

    LOS ANGELES , Nov. 30, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, ...

  • Stellar Biotechnologies to Present at BlueTech Summit
    PR Newswire4 months ago

    Stellar Biotechnologies to Present at BlueTech Summit

    LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, announced today that Stellar President and CEO Frank R. Oakes will present at the 10th Annual BlueTech Summit to be held November 5-9, 2018 in San Diego, California. Mr. Oakes is scheduled to participate in the Biomedicines panel discussion and presentation on Wednesday, November 7, 2018 at 2:15 pm Pacific Time at the InterContinental San Diego hotel. The conference, which focuses on sustainable ocean and water technologies, is presented by The Maritime Alliance, a non-profit organizer of San Diego's BlueTech cluster and BlueTech Week.

  • Zacks Small Cap Research5 months ago

    SBOT: NCI Supply Contract: Highlights Growing Interest of KLH for Cancer Immunotherapies

    Securing more KLH supply agreements has been one of Stellar Biotechnologies’ (SBOT) strategic objectives and earlier this month the company made additional headway on that goal. In early September Stellar announced that they entered an agreement with the U.S. National Institutes of Health (NIH) to supply their proprietary KLH for government-sponsored studies.

  • Do Institutions Own Shares In Stellar Biotechnologies Inc (NASDAQ:SBOT)?
    Simply Wall St.5 months ago

    Do Institutions Own Shares In Stellar Biotechnologies Inc (NASDAQ:SBOT)?

    If you want to know who really controls Stellar Biotechnologies Inc (NASDAQ:SBOT), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunkRead More...

  • PR Newswire6 months ago

    Stellar Biotechnologies to Supply KLH to National Institutes of Health

    LOS ANGELES, Sept. 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, autoimmune disease and cancers, among other diseases, announced today that it has been contracted by the U.S. National Institutes of Health (NIH) to supply the company's Stellar KLH protein for government-sponsored clinical studies. The company reported that it has initiated product manufacturing for the NIH's National Cancer Institute, which plans to use a vialed formulation of Stellar KLH in dendritic cell-based cancer therapies.

  • PR Newswire6 months ago

    Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference

    LOS ANGELES, Aug. 28, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, announced today that Stellar CEO and President Frank R. Oakes will present at the H. C. Wainwright 20th Annual Global Investment Conference to be held September 4-6, 2018 in New York City. The company will provide an overview of its Stellar KLH business and recent corporate activities. Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccine pipelines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function.

  • PR Newswire7 months ago

    Stellar Biotechnologies Reports Third Quarter Financial Results

    LOS ANGELES , Aug. 8, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, ...

  • ACCESSWIRE7 months ago

    Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks

    Stock Research Monitor: OGEN, ONCE, and SBOT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • Zacks Small Cap Research7 months ago

    SBOT: Neovacs Announces Ph2 Lupus Results, “Will Enable Us To Move Into Ph3…”

    Last week Neovacs announced results of its phase IIb trial investigating safety and efficacy of their IFNa-Kinoid (IFN-K) candidate in the treatment of systemic lupus erythematosus (SLE). While one of the two co-primary endpoints did not reach statistical significance, the other did (and, in fact, was highly statistically significant). In addition, one of the two secondary efficacy endpoints was statistically significant, while the other showed a positive trend towards significance (although did not reach it).

  • Stellar Biotechnologies’ Partner Neovacs’s Favorable Study Data
    Market Realist8 months ago

    Stellar Biotechnologies’ Partner Neovacs’s Favorable Study Data

    Today, Stellar Biotechnologies’ stock was up ~10.5% in premarket trading as the company issued a statement on positive study results published by its partner Neovacs. Neovacs posted favorable Phase 2b study data for IFNalpha Kinoid in patients with moderate to severe lupus or SLE (systemic lupus erythematosus), an autoimmune disease in which healthy tissues come under attack by the immune system. Stellar Biotechnologies provides Keyhole Limpet Hemocyanin (KLH) to Neovacs.

  • PR Newswire8 months ago

    Stellar Issues Statement on Favorable Clinical Study Results

    LOS ANGELES , July 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines, today issued a ...

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Heron Therapeutics and Stellar Biotechnologies

    NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Biotech stocks Heron Therapeutics and Stellar Biotechnologies were gaining like wildfire in Thursday’s trading session with both companies releasing positive ...

  • Why Stellar Biotechnologies Saw Pre-Market Gains of 84%
    Market Realist8 months ago

    Why Stellar Biotechnologies Saw Pre-Market Gains of 84%

    Today, Stellar Biotechnologies (SBOT) rose ~84% in the pre-market session on the news of the successful completion of a study related to the company’s KLH (keyhole limpet hemocyanin) products. The study was focused on the molecular composition of these products. The KLH protein is used as a carrier in therapeutic and research applications extensively. The study, which was a quality analysis, was part of the company’s initiatives to support clinical trials of drug candidates in later stages that utilize the KLH protein as a carrier molecule and immunostimulant.

  • Benzinga8 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Casi Pharmaceuticals Inc (NASDAQ: CASI ) stock was ...

  • PR Newswire8 months ago

    Stellar Reports Positive Research Results from KLH Glycosylation Study

    LOS ANGELES, June 21, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today announced the successful completion of a research study focused on the molecular composition of the company's KLH products. The quality analysis was completed as part of Stellar's initiatives to support later stage clinical trials of drug candidates that utilize KLH as a carrier molecule and immunostimulant. As part of the study, third party researchers analyzed the patterns of carbohydrates that attach to the KLH protein through a biologic process known as glycosylation.

  • ACCESSWIRE8 months ago

    Stock Performance Review on Sesen Bio and Three Other Biotech

    LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • How Has Stellar Biotechnologies Inc’s (NASDAQ:SBOT) Performed Against The Industry?
    Simply Wall St.9 months ago

    How Has Stellar Biotechnologies Inc’s (NASDAQ:SBOT) Performed Against The Industry?

    After looking at Stellar Biotechnologies Inc’s (NASDAQ:SBOT) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

  • ACCESSWIRE9 months ago

    Today’s Research Reports on Stocks to Watch: Recro Pharma and Stellar Biotechnologies

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / Recro Pharma shares saw a huge drop and hit a new low after the FDA declined to approve the company's IV meloxicam, which was supposed to be the company's first ...

  • PR Newswire9 months ago

    Stellar Biotechnologies Announces Exercise of Warrants Resulting in Cash Proceeds of $3 Million

    LOS ANGELES , May 24, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT, "Stellar" or the "Company"), a leading manufacturer of a key protein utilized in multiple immunotherapy ...

  • PR Newswire9 months ago

    Stellar Achieves Robust Viral Clearance for Manufacturing Process

    LOS ANGELES, May 24, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today announced that third-party trial results have demonstrated that the company's KLH manufacturing methods achieve robust viral clearance. This clearance step is a key quality assurance milestone under Stellar's initiatives to increase the scalability and throughput capacity of its manufacturing processes. Results from testing completed by Texcell, a contract testing organization for viral safety, demonstrated that Stellar's manufacturing process for its most widely used formulation effectively removes three representative viruses, and meets suggested regulatory criteria for robustness.